KF-0210 is designed to regulate the tumor microenvironment, enhance anti-tumor immune function, and inhibit tumor growth and metastasis. This clinical trial will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of KF-0210. It is the first project in Keythera Biopharmaceuticals’new drug development pipeline to enter the clinical research stage and is being conducted in multiple centers in Australia and China.

With the completion of the Series A+ financing, Keythera Biopharmaceuticals will continue to support its new drug development efforts, including pipeline expansion, clinical research expansion, exploration of different combination therapies, and development of new indications to address unmet medical needs.

Dr. Yongqi Deng, Chairman and CEO of Keythera Biopharmaceuticals, expressed gratitude for the trust and support of well-known investment institutions, emphasizing the company's mission to benefit patients and improve their quality of life. The company will continue to strive for excellence in the field of new drug development and hopes that KF-0210 and other products in the Keythera pipeline can benefit cancer patients at an early stage.

Yijing Capital stated that the founding team of Keythera Biopharmaceuticals has years of experience in small molecular drug development and possesses solid research and development capabilities. With an international pipeline layout strategy and rigorous and efficient product development, Yijing Capital is honored to support Keythera Biopharmaceuticals to accelerate clinical advancement and technological platform development, ultimately providing accessible and effective drugs for global cancer and autoimmune disease patients.

About Keythera Pharmaceuticals

Located in Biobay，Suzhou Industrial Park, China, Keythera  Biopharmaceuticals is a biopharmaceutical company founded by a team of experienced professionals who have returned from the United States. The company is dedicated to developing innovative therapies to address unmet medical needs in China and globally. Keythera  Biopharmaceuticals has a team of top-level professionals and managers， and plans to establish internal drug screening platforms and drug evaluation technology platforms while developing its own pipeline of new drug products, aiming to build a solid foundation for the company's long-term innovative capabilities.

About Yijing Capital

Established in 2015, Yijing Capital conducts primary market equity investments and fund investments with its own funds and private equity funds. Guided by the philosophy of "helping companies innovate and grow, promoting industrial optimization and upgrading, and advancing social development and progress," Yijing Capital focuses on the healthcare, TMT & consumer goods, and hardcore technology sectors. It specializes in investing in early-stage and growth-stage companies that create high value and high-tech innovations. In the medical field, Yijing Capital has invested in leading companies in various sub-sectors, including Weiernuo Pediatrics, Da Medical Group, Hanyu Medical, Surgical Robots, Zhi Dao Biology, Messe Medical, and Opmai.

About Trend Investment

Trend Investment (overseas USD fund manager) and its domestic RMB fund manager (Shang Yiguanxi) specialize in private equity investments. They share a common research and fund management team, focusing on two sectors: biopharmaceuticals/medical and TMT (Technology, Media, and Telecommunications). Their investment portfolio in the biopharmaceuticals/medical field includes innovative drug companies such as Epimab, Healx, Elicio, Yaqrit Discovery, Leads Biolabs, Phoremost, vaccine company Emergex, and medical device company Cipher Surgical, et al. 

Keythera Biopharmaceuticals
Website: http://keytherapharma.com